Screening Breast & Ovarian Cancers

HEREDITARY BREAST AND OVARIAN CANCER   6/2/07

Personal or family history of:

  1. Breast Cancer before age 50
  2. Ovarian cancer at any age
  3. Bilateral breast cancer at any age
  4. Both breast cancer and ovarian cancer at any age
  5. Male breast cancer at any age
  6. Askenazi Jewish ancestry with breast or ovarian cancer at any age
  7. > or = to 50 y/o w/breast cancer and a family history of breast and/or ovarian cancer.
  8. ==================================================


Recommendations from the United States Preventive Services Task Force on who should be offered genetic testing for BRCA mutations=================================================

A family history of breast or ovarian cancer that includes a relative with a known deleterious BRCA mutation
For non-Ashkenazi Jewish women:
Two first-degree relatives with breast cancer, one of whom was diagnosed at age 50 or younger
A combination of three or more first or second-degree relatives with breast cancer regardless of age at diagnosis
A combination of both breast and ovarian cancer among first and second-degree relatives
A first-degree relative with bilateral breast cancer
A combination of two or more first or second degree relatives with ovarian cancer, regardless of age at diagnosis
A first or second-degree relative with both breast and ovarian cancer at any age
History of breast cancer in a male relative=====================================================
For women of Ashkenazi Jewish descent:
Any first-degree relative (or two second degree relatives on the same side of the family) with breast or ovarian cancer

U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005; 143:355.

This entry was posted on Friday, December 26th, 2008 at 5:39 pm and is filed under Breast Cancer, Gynecology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.